Summary of S. 3797: Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Overview

The Prohibiting Tianeptine and Other Dangerous Products Act of 2026 is a bill introduced in the U.S. Senate that aims to amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements.

Key Provisions

• Prohibits the introduction or delivery into interstate commerce of any product marketed as a dietary supplement that does not meet the legal definition of a dietary supplement under the Federal Food, Drug, and Cosmetic Act.
• Prohibits the introduction or delivery into interstate commerce of dietary supplements that have been prepared, packed, or held with the assistance of, or at the direction of, a person who has been debarred under the Act.
• Expands the FDA's import exclusion and product seizure authorities to cover violations of these new prohibited acts.

Impact

• This bill targets potentially dangerous or mislabeled dietary supplements, including those containing the substance tianeptine, which has been linked to abuse and adverse health effects.
• It aims to give the FDA more tools to keep unsafe or illegal supplements out of the U.S. market and off store shelves.
• The new prohibited acts and enforcement provisions could lead to increased regulatory scrutiny and potential penalties for dietary supplement manufacturers and distributors that do not comply with the law.

Procedural Details

• The bill was introduced in the Senate on February 5, 2026 by Senators Richard Durbin and Richard Blumenthal.
• It was referred to the Senate Committee on Health, Education, Labor, and Pensions for consideration.

Overall, this legislation represents an effort by lawmakers to address concerns about the proliferation of potentially dangerous or mislabeled dietary supplements in the U.S. market.